RSV Vaccine Eligibility for Older Adults

Respiratory Syncytial Virus (RSV) was once thought of as a primary concern for infants, but medical data clearly shows it poses a significant threat to older adults as well. With new vaccines available and updated guidelines released by the CDC in mid-2024, understanding your eligibility is vital for protecting your lung health this season.

Updated CDC Guidelines: Who Needs the Shot?

The Centers for Disease Control and Prevention (CDC) recently simplified the recommendations for the RSV vaccine. In previous years, the guidance relied on “shared clinical decision-making,” which meant you had to debate the pros and cons with your doctor. Now, the guidance is much more direct.

As of the 2024-2025 respiratory season, the CDC recommends a single dose of the RSV vaccine for the following groups:

1. Adults Aged 75 and Older

If you are 75 or older, the recommendation is universal. You should receive the RSV vaccine regardless of your underlying health status. At this age, the immune system naturally weakens, making the risk of severe hospitalization from RSV much higher. If you have not yet received a dose, you are eligible immediately.

2. Adults Aged 60 to 74 with Increased Risk

If you fall into this age bracket, you are eligible and recommended to get the vaccine if you have specific chronic medical conditions or risk factors. These conditions make you more likely to suffer from severe respiratory illness if you catch the virus.

Qualifying conditions include:

  • Chronic lung diseases: This includes COPD (chronic obstructive pulmonary disease), asthma, and interstitial lung disease.
  • Cardiovascular diseases: Heart failure and coronary artery disease are primary qualifiers.
  • Diabetes: Specifically if it has caused organ damage, though generally moderate-to-severe diabetes is a qualifying factor.
  • Kidney or Liver disorders: Moderate or severe chronic kidney disease or liver disease.
  • Neurologic conditions: Neuromuscular conditions that impair swallowing or breathing.
  • Immune compromise: This covers individuals undergoing chemotherapy, organ transplant recipients, or those taking immunosuppressive medication.
  • Frailty: Individuals residing in nursing homes or other long-term care facilities.

Important Note on Revaccination

Currently, the RSV vaccine is not an annual shot like the influenza vaccine. If you received an RSV vaccine last season, you do not need another dose this year. The current data suggests that protection extends through a second season, and health officials have not yet authorized a booster dose.

Available Vaccine Brands and Options

There are currently three FDA-approved RSV vaccines available for older adults. The CDC does not recommend one over the others; the best vaccine is simply the one available at your pharmacy or doctor’s office.

Arexvy (GSK): Approved in May 2023, Arexvy was the first RSV vaccine authorized for use in the United States. It is a protein subunit vaccine that includes an adjuvant. An adjuvant is an ingredient added to enhance the body’s immune response, which is particularly helpful for older immune systems.

Abrysvo (Pfizer): Also approved in May 2023, Abrysvo is a bivalent protein subunit vaccine. Unlike Arexvy, it does not contain an adjuvant. It is designed to protect against both RSV-A and RSV-B substrains.

mRESVIA (Moderna): Approved more recently in May 2024, this is the newest option. It utilizes mRNA technology, the same platform used for the widely distributed COVID-19 vaccines. It teaches your cells to produce a protein that triggers an immune response against RSV.

Efficacy: How Well Do They Work?

Clinical trials have demonstrated high efficacy for these vaccines against lower respiratory tract disease (LRTD), which involves infection deep in the lungs (pneumonia or bronchitis).

  • Reduction in Severe Illness: Studies showed that Arexvy and Abrysvo reduced the risk of RSV-related lung infections by roughly 80% to 90% during the first season after vaccination.
  • Durability: While protection dips slightly over time, data indicates that the vaccines remain effective through a second RSV season. This durability is why health officials currently recommend it as a one-time dose rather than an annual requirement.

Safety and Side Effects

The safety profile for these vaccines is well-established. Most side effects are mild and temporary.

Common reactions include:

  • Pain, redness, or swelling at the injection site.
  • Fatigue.
  • Headache.
  • Muscle or joint pain.

These symptoms typically resolve within 24 to 48 hours. In very rare instances, neurological conditions like Guillain-Barré syndrome (GBS) were reported in trials. The rate was approximately 1.5 to 3 cases per million doses administered. Health experts agree that the benefit of preventing severe RSV pneumonia outweighs this extremely low risk.

Cost and Insurance Coverage

Understanding how to pay for the vaccine is just as important as knowing if you are eligible.

Medicare Part D: This is the most critical detail for seniors. The RSV vaccine is covered under Medicare Part D (prescription drug coverage), not Part B (medical coverage).

  • Because of the Inflation Reduction Act, all vaccines recommended by the ACIP (Advisory Committee on Immunization Practices) are free for people with Medicare Part D. You should pay $0 out of pocket.
  • Warning: If you try to get this at a doctor’s office that cannot bill Part D, you might be asked to pay upfront and seek reimbursement. It is usually easier and cheaper to get this shot at a pharmacy (like CVS, Walgreens, or Walmart) that processes Part D claims daily.

Private Insurance: Most private health insurance plans are required to cover the vaccine at no cost to the patient if they use an in-network provider. However, you should always check your specific plan details before your appointment.

Frequently Asked Questions

Can I get the RSV vaccine at the same time as my flu shot? Yes. You can receive the RSV vaccine, the flu shot, and the COVID-19 vaccine during the same visit. However, getting them in different arms is often recommended to reduce soreness. Be aware that co-administration might slightly increase the likelihood of temporary side effects like fatigue or headache.

When is the best time to get the RSV shot? RSV season typically starts in late fall and peaks in the winter. Ideally, you should get vaccinated in late summer or early fall (September or October) to ensure maximum immunity before the virus begins circulating widely. However, if you miss this window, getting vaccinated later in the season is still beneficial.

If I am 65 and healthy, do I need the shot? Under the new guidelines, if you are between 60 and 74 and do not have any of the chronic risk factors listed above (like heart disease or diabetes), the CDC does not currently recommend the vaccine for you. The recommendation becomes universal only once you turn 75.

Is the vaccine a live virus? No. None of the three approved vaccines (Arexvy, Abrysvo, or mRESVIA) contain live virus. You cannot catch RSV from the vaccine. They are composed of proteins or mRNA instructions that train your immune system to recognize the virus.